Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll

• 78% of Canadians not opposed to use of psilocybin to ease distress of terminally ill patients
• 59% of Canadians approve of such therapies
• Approval rating boosted by positive study results

Do you have a friend or relative who is (unfortunately) suffering from some terminal illness? Why not give them some ‘magic mushrooms’ to ease their distress?

A few years ago, such a suggestion would have been viewed as ridiculous or even abhorrent. But no longer.

Today, thanks to the Cannabis Revolution, psychedelic drug therapy is seeing a rapid thaw in public attitudes. A new Canadian poll on the medicinal use of psychedelic drugs illustrates this rising tide of acceptance.
 

A poll conducted in Canada by psychedelics non-profit advocacy group, TheraPsil, reported rising support among Canadians for the use of psilocybin (the psychoactive compound in magic mushrooms) for the terminally ill.

It was a two-staged poll. First, respondents were simply asked whether they approved of the use of psilocybin as a treatment option for end-of-life distress.
 

• 41% of Canadians somewhat or strongly supported this
• 22% were ambivalent toward this idea

TheraPsil has interpreted these ambivalent responses as a soft “yes” to the use of psilocybin, which may be stretching the analysis slightly. What can be said was that less than 40% of Canadians were opposed to the use of psilocybin to ease the distress of terminally ill patients.

Then TheraPsil repeated the question, but with an additional caveat added.
 

For this question:
 

• 59% of Canadians were somewhat or strongly in favor
• An additional 19% were ambivalent toward this idea

Armed with the knowledge that a clinical study reported “large and significant decreases in depression and anxiety”, respondents reacted with a significant increase in support for the use of psilocybin in this context.

The percentage of those somewhat/strongly in favor immediately rose by 44% (from 41% to 59%) as soon as respondents knew that there was actual science behind this proposed therapy.

This alerts both psychedelics companies and psychedelics investors to two important dynamics:
 

As soon as respondents were fed the science on the use of psilocybin to relieve anxiety/depression among the terminally ill, support jumped. This suggests that psychedelics companies and the industry as a whole can benefit strongly from a commitment to public education and greater publicity regarding psychedelic drug research.

Canadians, in particular, are very open to persuasion on the merits of psychedelic drug use. Here, psychedelics companies can thank the cannabis industry.

The Cannabis Revolution has resulted in cannabis being fully legalized across Canada and partially or fully legalized in most U.S. states.

Canadians (and Americans) have seen legalized cannabis successfully integrated into our societies – with none of the negative repercussions that anti-drug zealots ‘warned us’ about. Clearly, this has gone a long way in reducing anti-drug phobias that were a product of the long-and-disastrous War on Drugs.

The psychedelics industry is the beneficiary of this rapid change in public attitudes towards previously (and currently) prohibited drugs.

Framed in opposite terms, opposition to the use of psilocybin among Canadians fell from ~37% to ~22% as soon as respondents were provided with clinical study results. That’s a reduction of 40% in the percentage of respondents opposed to psilocybin therapy.

Attitudes among Americans can be expected to show lower levels of support (at this point), parallel to their somewhat greater resistance to cannabis legalization. However, the general dynamics at work here should also apply to U.S. consumers/voters.

The Cannabis Revolution has been a difficult journey, as evidenced by the stalling of regulatory reform in the U.S. However, for the psychedelics industry, the Cannabis Revolution may make its own journey significant less difficult.